FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 231 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Beloved Preschool Teacher Dies of Breast Cancer, Leaving Behind 9-Year-Old Son December 2, 2021 Determination of the Incidence of Driver Mutations in Patients with NSCLC... March 24, 2021 Antioxidant Use Before And During Chemo Increases Risk Of Relapse, Death... March 6, 2020 Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... May 5, 2020 Load more HOT NEWS Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer...
